About
Nanoparticle AIM Therapy, Cell Therapies
Areas of Focus
Categories
NanotechStem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Team (8)
Daniel Bednarik Ph.D.
Daniel Bednarik Ph.D.
NexImmune
team_member
Jack Ragheb
Jack Ragheb
NexImmune
team_member
Karen Haslbeck
Karen Haslbeck
NexImmune
team_member
Kristi Jones
Kristi Jones
NexImmune
team_member
Mathias Oelke, Ph.D.
Mathias Oelke, Ph.D.
NexImmune
team_member
Matt Schiller
Matt Schiller
NexImmune
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
67
By Phase
PHASE1: 1PHASE1/PHASE2: 2
By Status
NOT_YET_RECRUITING: 1SUSPENDED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05582590Lead Sponsor
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
PHASE1Not yet recruiting
36 participants
Started: Mar 31, 2025 · Completed: Aug 25, 2027
NCT04505813Lead Sponsor
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
PHASE1/PHASE2Suspended
9 participants
Started: Aug 17, 2020 · Completed: Dec 31, 2025
NCT04284228Lead Sponsor
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
PHASE1/PHASE2Active, not recruiting
22 participants
Started: Feb 20, 2020 · Completed: Mar 31, 2025
Locations (1)
Headquarters
Gaithersburg, MD, United States
Map
Loading map...